colere.blog

Lenmeldy, a gene therapy owned by Orchard Therapeutics and used in the treatment of a rare genetic disease called early-onset metachromatic leukodystrophy (MLD), is the world’s most expensive drug with a $4.25 million price tag.

Why Is Lenmeldy So Expensive?

The primary reason why gene therapies like Lenmeldy have such high prices is that they cannot be mass-produced and sold to millions of people like classical drugs, and their production process is extraordinarily complex and costly. The main factors contributing to this situation are:

1. One-Time (Curative) Treatment Model: These drugs are not maintenance medications used daily or at regular intervals. It is a single-dose application that eliminates the disease for life or halts its progression. Drug manufacturers incorporate the long-term economic value, which saves the patient from hospital, care, and other treatment expenses throughout their life, into this single price.
2. Personalized and Complex Production Process: Treatments like Lenmeldy involve extremely laborious biotechnological processes that require collecting the patient’s own stem cells, genetically modifying them in a laboratory with a functional copy of the missing/defective gene, and re-administering them to the patient. The process is entirely personalized for each patient from start to finish.
3. Extremely Narrow Market (Rare Disease): Diseases like metachromatic leukodystrophy (MLD) are very rare, so the patient pool for the drug is small. The costs of R&D, clinical trials, and special facility investments must be recovered from the very small number of patients who use this drug.
4. Long-Term Cost Analyses: Health economics organizations (e.g., ICER) calculate that such gene therapies prevent enormous care costs and loss of labor by enabling children to walk, talk, and lead a normal life in the long term; pricing is determined based on this “health and life value” criterion.

Lenmeldy’s Production Process

Lenmeldy (and similar autologous gene therapies), unlike chemical drugs mass-produced in thousands of boxes in factories, is custom-produced for each patient from scratch in a laboratory setting. The production process consists of sequential and extremely high-precision stages:

1. Stem Cell Collection (Apheresis): The patient’s (child’s) own blood stem cells (hematopoietic stem cells) are collected from their body through a special medical procedure (apheresis). Since these cells are the patient’s own tissue, they eliminate the risk of the body rejecting them.
2. Genetic Modification (Laboratory Process): These collected stem cells are sent to the laboratory. A healthy and functional copy of the ARSA gene, which is missing or mutated in the disease, is integrated into the cells’ DNA via a safely modified lentiviral vector (carrier virus). This enables the cells to produce the missing enzyme.
3. Quality Control and Safety Tests: Before the genetically modified cells are returned to the patient, they must undergo weeks of very strict quality control tests for sterility, viability, genetic integration rate, and purity. Since each batch belongs only to that single patient, it is tested from scratch every time.
4. Administration Process: The cells, produced and frozen under special conditions, are delivered to the hospital. Before this procedure, the patient undergoes chemotherapy (myeloablative conditioning) to clear defective cells from the bone marrow. Afterward, these genetically corrected stem cells are administered to the patient via infusion through a vein.